Effect of short-term interferon-β treatment on cytokines in multiple sclerosis: Significant modulation of IL-17 and IL-23

Cytokine

Volumn 59, Issue 2, 2012, Pages 400-402

  Kürtüncü, Murat ^a   Tüzün, Erdem ^b   Türkoĝlu, Recai ^c   Petek Balci, Belgin ^d   Içöz, Sema ^e   Pehlivan, Münevver ^e   Birişik, Ömer ^e   Ulusoy, Canan ^b   Shugaiv, Erkingül ^e   Akman Demir, Gülşen ^f   Eraksoy, Mefküre ^e  

^a ACIBADEM UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c HAYDARPASA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^d Haseki Educational and Research Center ^*  (Turkey)

^e ISTANBUL UNIVERSITY   (Turkey)

^f ISTANBUL BILIM UNIVERSITY   (Turkey)

Author keywords

Cytokine; Interleukins; Multiple sclerosis; Th1; Th17

Indexed keywords

BETA1A INTERFERON; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 9; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; SHORT COURSE THERAPY; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH1 TH2 BALANCE; TH17 CELL; TH2 CELL; UPREGULATION;

ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNITY; INTERFERON-BETA; INTERLEUKIN-17; INTERLEUKIN-23; MALE; MULTIPLE SCLEROSIS; TH17 CELLS; TIME FACTORS;

EID: 84862308491     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.05.004     Document Type: Article

References (26)

1. Hemmer B., Nessler S., Zhou D., Kieseier B., Hartung H.P. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol 2006, 2:201-211.
2. Prinz M., Kalinke U. New lessons about old molecules: how type I interferons shape Th1/Th17-mediated autoimmunity in the CNS. Trends Mol Med 2010, 16:379-386.
3. Segal B.M. Th17 cells in autoimmune demyelinating disease. Semin Immunopathol 2010, 32:71-77.
4. Hamamcioglu K., Reder A.T. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis. Mult Scler 2007, 13:459-470.
5. Ochi H., Feng-Jun M., Osoegawa M., Minohara M., Murai H., Taniwaki T., et al. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b. J Neurol Sci 2004, 222:65-73.
6. Rudick R.A., Ransohoff R.M., Lee J.C., Peppler R., Yu M., Mathisen P.M., et al. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 1998, 50:1294-1300.
7. Río J., Montalban X. Interferon-beta 1b in the treatment of multiple sclerosis. Expert Opin Pharmacother 2005, 6:2877-2886.
8. Alexander J.S., Harris M.K., Wells S.R., Mills G., Chalamidas K., Ganta V.C., et al. Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b. Mult Scler 2010, 16:801-809.
9. Axtell R.C., de Jong B.A., Boniface K., van der Voort L.F., Bhat R., De Sarno P., et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010, 16:406-412.
10. Sellner J., Greeve I., Findling O., Kamm C.P., Minten C., Engelhardt B., et al. Effect of interferon-beta and atorvastatin on Th1/Th2 cytokines in multiple sclerosis. Neurochem Int 2008, 53:17-21.
11. Wiesemann E., Deb M., Hemmer B., Radeke H.H., Windhagen A. Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis. Clin Immunol 2008, 128:306-313.
12. Nicoletti F., Di Marco R., Patti F., Zaccone P., L'Episcopo M.R., Reggio E., et al. Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha. Cytokine 2000, 12:682-687.
13. Losy J., Michałowska-Wender G. In vivo effect of interferon-beta 1a on interleukin-12 and TGF-beta(1) cytokines in patients with relapsing-remitting multiple sclerosis. Acta Neurol Scand 2002, 106:44-46.
14. Mirandola S.R., Hallal D.E., Farias A.S., Oliveira E.C., Brandão C.O., Ruocco H.H., et al. Interferon-beta modifies the peripheral blood cell cytokine secretion in patients with multiple sclerosis. Int Immunopharmacol 2009, 9:824-830.
15. Gayo A., Mozo L., Suárez A., Tuñon A., Lahoz C., Gutiérrez C. Long-term effect of IFNbeta1b treatment on the spontaneous and induced expression of IL-10 and TGFbeta1 in MS patients. J Neurol Sci 2000, 179:43-49.
16. Lünemann J.D., Aktas O., Gniadek P., Zschenderlein R., Zipp F. Downregulation of transforming growth factor-beta1 in interferon-beta1a-treated MS patients. Neurology 2001, 57:1132-1134.
17. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P., Kappos L., et al. Revisions to the "McDonald Criteria" Ann Neurol 2005, 58(2005):840-846.
18. Chen Y., Langrish C.L., McKenzie B., Joyce-Shaikh B., Stumhofer J.S., McClanahan T., et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 2006, 116:1317-1326.
19. Chen M., Chen G., Nie H., Zhang X., Niu X., Zang Y.C., et al. Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T Cells in MS. Eur J Immunol 2009, 39:2525-2536.
20. Graber J.J., Ford D., Zhan M., Francis G., Panitch H., Dhib-Jalbut S. Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response. J Neuroimmunol 2007, 185:168-174.
21. Carrieri P.B., Ladogana P., Di Spigna G., de Leva M.F., Petracca M., Montella S., et al. Interleukin-10 and interleukin-12 modulation in patients with relapsing-remitting multiple sclerosis on therapy with interferon-beta 1a: differences in responders and non responders. Immunopharmacol Immunotoxicol 2008, 30:1-9.
22. Ossege L.M., Sindern E., Patzold T., Malin J.P. Immunomodulatory effects of interferon-beta-1b in patients with multiple sclerosis. Int Immunopharmacol 2001, 1:1085-1100.
23. Li H., Nourbakhsh B., Ciric B., Zhang G.X., Rostami A. Neutralization of IL-9 ameliorates experimental autoimmune encephalomyelitis by decreasing the effector T cell population. J Immunol 2010, 185:4095-4100.
24. Soroosh P., Doherty T.A. Th9 and allergic disease. Immunology 2009, 127:450-458.
25. Nowak E.C., Noelle R.J. Interleukin-9 as a T helper type 17 cytokine. Immunology 2010, 131:169-173.
26. Akdis M., Burgler S., Crameri R., Eiwegger T., Fujita H., Gomez E., et al. Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases. J Allergy Clin Immunol 2011, 127:701-721.